VERU Veru (VERU) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000863894
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
25
13F, latest reported quarter
What the filings say about VERU
Insiders, 180 days
+$4.8K net bought
1 buyer
Veru insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, VERU INC. insiders bought a net $4.8K of stock across 14 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 24, 2024.
- The trade is 78.3% of the 2,300 shares held after it.
- No other insider bought within 30 days.
- 25 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer BARNETTE K GARY bought about $4.8K of VERU on Aug 13, 2026, the largest insider purchase at the company since 2025; 25 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Feb 18, 2025.
- The trade is 21.9% of the 250,000 shares held after it.
- No other insider bought within 30 days.
- 25 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Rankowitz Michael L bought about $31.7K of VERU on Feb 19, 2025; 25 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 48.8% of the 195,279 shares held after it.
- No other insider bought within 30 days.
- 25 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Rankowitz Michael L bought about $52.4K of VERU on Feb 18, 2025, the largest insider purchase at the company on our record; 25 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 15, 2024.
- The trade is 0.5% of the 774,736 shares held after it.
- 1 other insider bought within 30 days.
- 25 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Corporate Officer FISCH HARRY bought about $5.0K of VERU on May 24, 2024; 1 other insider bought within 30 days and 25 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 5,000 shares held after it.
- 1 other insider bought within 30 days.
- 25 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer BARNETTE K GARY bought about $6.7K of VERU on May 24, 2024; 1 other insider bought within 30 days and 25 funds added in the latest 13F quarter.14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$4.8K over 180 days
+$4.8K over 90 days
more than 65% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
25 funds bought in last quarter
below 65% of Pharma & Biotech
Revenue
+3.6% year over year
more than 50% of Pharma & Biotech
Margin
-134.6% net margin
below 60% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
9.5% of the float short (float per yahoo 2026-10-27) · 4.9 days to cover · settled 2026-10-15
more than 67% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch VERU
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-38.7%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns VERU: institutional holders (13F)
13F holdings, latest reported quarter
698,439 sh
$2.2M
238,556 sh
$746.7K
210,843 sh
$659.9K
167,084 sh
$523.0K
164,450 sh
$514.7K
Congress trades in VERU
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
VERU planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
VERU mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$155.2K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$10.5K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$217.8K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$495.1K position · as of 2026-06-30
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$1.7M position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$20.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 2
1 active
4
Phase 3
0 active
2
Multi-phase
0 active
What changed recently
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobo
2026-09-05 · Recruiting → Active Not Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $4.8K bought by insiders over 180 days, 25 funds added last quarter. Each figure is a federal filing, dated the day it went public.
VERU financials
Revenue growth
+3.6%
XBRL, annual
Net margin
-134.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM VERU
| FY Sep 2025 | n/a |
| FY Sep 2024 | $16.9M |
| FY Sep 2023 | $16.3M |
| FY Sep 2022 | $39.4M |
| FY Sep 2021 | $61.3M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | n/a |
| Sep 2024 | $6.7M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM VERU
| FY Sep 2025 | n/a |
| FY Sep 2024 | -223.9% |
| FY Sep 2023 | -571.6% |
| FY Sep 2022 | -213.5% |
| FY Sep 2021 | +12.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -128.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$26.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM VERU
| FY Sep 2025 | -$30.0M |
| FY Sep 2024 | -$21.8M |
| FY Sep 2023 | -$88.7M |
| FY Sep 2022 | -$48.2M |
| FY Sep 2021 | -$15.9M |
| Jun 2026 | -$5.5M |
| Mar 2026 | -$8.9M |
| Dec 2025 | -$6.2M |
| Sep 2025 | -$5.5M |
| Jun 2025 | -$5.5M |
| Mar 2025 | -$7.7M |
| Dec 2024 | -$11.3M |
| Sep 2024 | -$4.4M |
At each fiscal year end
Single quarter
Debt to equity
0.06x
long-term debt only, 2018-12-31 (91 months older than the period end); equity 2026-06-30
Debt to equity VERU
| FY Sep 2025 | 0.09x |
| FY Sep 2024 | 0.05x |
| FY Sep 2023 | 0.09x |
| FY Sep 2022 | 0.02x |
| FY Sep 2021 | 0.01x |
| Jun 2026 | 0.06x |
| Mar 2026 | 0.05x |
| Dec 2025 | 0.05x |
| Sep 2025 | 0.09x |
| Jun 2025 | 0.11x |
| Mar 2025 | 0.08x |
| Dec 2024 | 0.06x |
| Sep 2024 | 0.05x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-15.30x
TTM operating cash flow over long-term debt only, 2018-12-31 (91 months older than the period end)
Cash flow to debt VERU
| FY Sep 2025 | -17.65x |
| FY Sep 2024 | -12.74x |
| FY Sep 2023 | -51.69x |
| FY Sep 2022 | -27.90x |
| FY Sep 2021 | -9.15x |
| Jun 2026 | -15.30x |
| Mar 2026 | -15.31x |
| Dec 2025 | -14.61x |
| Sep 2025 | -17.65x |
| Jun 2025 | -16.98x |
| Mar 2025 | -17.08x |
| Dec 2024 | -15.86x |
| Sep 2024 | -12.74x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-62.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity VERU
| FY Sep 2025 | -89.7% |
| FY Sep 2024 | -145.4% |
| FY Sep 2023 | -181.8% |
| FY Sep 2022 | -70.8% |
| FY Sep 2021 | +8.0% |
| Jun 2026 | -62.3% |
| Mar 2026 | -50.0% |
| Dec 2025 | -60.0% |
| Sep 2025 | -89.7% |
| Jun 2025 | -123.5% |
| Mar 2025 | -109.7% |
| Dec 2024 | -98.4% |
| Sep 2024 | -145.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-42.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets VERU
| FY Sep 2025 | -50.4% |
| FY Sep 2024 | -68.5% |
| FY Sep 2023 | -100.5% |
| FY Sep 2022 | -53.6% |
| FY Sep 2021 | +6.4% |
| Jun 2026 | -42.3% |
| Mar 2026 | -36.8% |
| Dec 2025 | -43.7% |
| Sep 2025 | -50.4% |
| Jun 2025 | -71.1% |
| Mar 2025 | -69.6% |
| Dec 2024 | -63.9% |
| Sep 2024 | -68.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital VERU
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-74.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed VERU
| FY Sep 2025 | -70.1% |
| FY Sep 2024 | -89.6% |
| FY Sep 2023 | -145.6% |
| FY Sep 2022 | -64.5% |
| FY Sep 2021 | +13.0% |
| Jun 2026 | -74.5% |
| Mar 2026 | -58.8% |
| Dec 2025 | -53.9% |
| Sep 2025 | -70.1% |
| Jun 2025 | -94.5% |
| Mar 2025 | -85.7% |
| Dec 2024 | -80.1% |
| Sep 2024 | -89.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing VERU
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | 775.45x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$16.7M
market value at close 2026-10-27 on 2026-08-06 shares, plus long-term debt only, 2018-12-31 (91 months older than the period end), minus cash 2026-06-30
Enterprise value VERU
| FY Sep 2025 | $41.6M |
| FY Sep 2024 | $1.1B |
| FY Sep 2023 | $642.1M |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | $28.1M |
| Mar 2026 | $9.6M |
| Dec 2025 | $3.1M |
| Sep 2025 | $41.6M |
| Jun 2025 | $836.9M |
| Mar 2025 | $699.0M |
| Dec 2024 | $926.6M |
| Sep 2024 | $1.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-67.0%
TTM free cash flow over market value at close 2026-10-27
FCF yield VERU
| FY Sep 2025 | -54.0% |
| FY Sep 2024 | -1.9% |
| FY Sep 2023 | -13.6% |
| FY Sep 2022 | -0.5% |
| FY Sep 2021 | -0.2% |
| Jun 2026 | -51.8% |
| Mar 2026 | -73.5% |
| Dec 2025 | -72.4% |
| Sep 2025 | -54.0% |
| Jun 2025 | -3.4% |
| Mar 2025 | -4.1% |
| Dec 2024 | -2.9% |
| Sep 2024 | -1.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing VERU
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-09 | 2024-09 | 2023-09 | 2022-09 | |
|---|---|---|---|---|
| Revenue | n/a | $16.9M | $16.3M | $39.4M |
| Gross profit | n/a | $5.9M | $7.6M | $30.6M |
| Operating income | -$24.8M | -$36.2M | -$93.8M | -$83.5M |
| Net income | -$22.7M | -$37.8M | -$93.2M | -$84.0M |
| EPS (diluted) | n/a | n/a | -1.10 | -1.05 |
| Operating cash flow | -$30.0M | -$21.7M | -$88.0M | -$47.5M |
| Cash | $15.8M | $24.9M | $9.6M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
VERU Stock Sonar score 6/7 axes
Find similar shapesCompareVERU ranks highest on insider conviction (60th percentile) and growth (50th), and lowest on risk and compliance (34th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
VERU filings, in plain words
Are Veru insiders buying or selling VERU?
In the 180 days to 2026-10-28, Veru insiders were net buyers, a net $4.8K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Veru insiders were net buyers of VERU, a net $4.8K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
